Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)
NICE recommends taking rituximab, fludarabine and cyclophosphamide together as a possible treatment for some people with relapsed or refractory chronic lymphocytic leukaemia (see below).
Who can have rituximab?
You should be able to have rituximab, fludarabine and cyclophosphamide together unless:
- you have had rituximab before (see below) or
- you have had fludarabine before and your condition did not respond to it or worsened within 6 months of treatment.
If you have had rituximab before
If this was part of a research study and one of the following conditions applies, you should still be able to have rituximab, fludarabine and cyclophosphamide together:
- the dose of rituximab you had was lower than normally used to treat chronic lymphocytic leukaemia or
- you had rituximab with other chemotherapy instead of fludarabine and cyclophosphamide.
If the conditions described above do not apply, you should only have rituximab again if you are taking part in a research study.
Rituximab with other chemotherapy
If your healthcare professional thinks that rituximab with other chemotherapy instead of fludarabine and cyclophosphamide is appropriate for you, you should only have rituximab if you are taking part in a research study.
This page was last updated: 01 October 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA193 Rituximab ar gyfer lewcemia lymffosytig cronig ail-wael neu nad yw'n ymateb mwyach i driniaeth: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.